

Suppl. Table 4. Influence of PLX4032 (20µM) or PLX4720 (20µM) on the vincristine (substrate of ABCB1 and ABCC1) or mitoxantrone (substrate of ABCG2) concentrations that reduce the cell viability by 50% (IC₅₀) in the BRAF wild-type melanoma cell lines IPC298 and SK-MEL-30 that both express ABCB1, ABCC1, and ABCG2.

	IC ₅₀ vincristine (ng/ml)	IC ₅₀ vincristine in the presence of PLX4032/PLX4720	fold sensitisation ¹	IC ₅₀ mitoxantrone (ng/mL)	IC ₅₀ mitoxantrone in the presence of PLX4032/PLX4720	fold sensitisation ²
PLX4032						
IPC298	2.74 ± 0.39	0.54 ± 0.07 ³ (73 ± 7) ⁴	5.11	1.54 ± 0.45	0.79 ± 0.08 ⁶ (75 ± 8) ⁴	1.96
SK-MEL-30	4.57 ± 1.49	0.42 ± 0.07 ³ (85 ± 9) ⁴	10.82	3.44 ± 0.44	1.73 ± 0.62 ⁶ (79 ± 11) ⁴	1.99
PLX4720						
IPC298	2.74 ± 0.39	0.83 ± 0.08 ³ (57 ± 10) ⁵	3.32	1.54 ± 0.45	0.69 ± 0.25 ⁶ (71 ± 13) ⁵	2.25
SK-MEL-30	4.57 ± 1.49	1.50 ± 0.62 ³ (73 ± 5) ⁵	3.04	3.44 ± 0.44	1.61 ± 0.08 ⁶ (77 ± 9) ⁵	2.14

¹ relative to vincristine alone

² relative to mitoxantrone alone

³ p < 0.05 relative to vincristine alone

⁴ cell viability in the presence of PLX4032 alone

⁵ cell viability in the presence of PLX4720 alone

⁶ p < 0.05 relative to mitoxantrone alone